TGF-β2 treatment enhances cytoprotective factors released from embryonic stem cells and inhibits apoptosis in infarcted myocardium
- 1 April 2011
- journal article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 300 (4) , H1442-H1450
Abstract
We investigated whether factors released from mouse embryonic stem (ES) cells primed with and without transforming growth factor (TGF)-β2 inhibit iodoacetic acid (IAA)- and H2O2-induced apoptosis in the cell culture system as well as after transplantation in the infarcted heart. We generated conditioned media (CMs) from ES cells primed with and without TGF-β2 and determined their effects on IAA- and H2O2-induced apoptosis in H9c2 cells. We also transplanted both ES-CMs in the infarcted heart to determine the effects on apoptosis and cardiac function after myocardial infarction (MI) at day (D)1 and D14. Terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL) staining, apoptotic ELISA, and cell viability data demonstrated significantly ( P < 0.05) reduced apoptosis with ES-CM compared with controls in both cell culture models. Moreover, TGF-β2-primed ES-CM (T-ES-CM) demonstrated enhanced beneficial effects, with further reduced ( P < 0.05) apoptosis compared with ES-CM, suggesting the a presence of additional cytoprotective released factors after TGF-β2 treatment. Next, our in vivo apoptosis data suggested significant decrease in apoptosis with both ES-CMs compared with MI alone at D1 and D14. Notably, T-ES-CM demonstrated significant ( P < 0.05) inhibition of apoptosis and fibrosis with improved cardiac function compared with ES-CM at D14, whereas no such effects were observed at D1. Next, we confirmed that apoptosis is mediated through a prosurvival Akt pathway. Moreover, we determined that after TGF-β2 treatment there was a two- to fivefold increase in cytoprotective released factors (interleukin-10, stem cell factor, tissue inhibitor of matrix metalloproteinase-1, and VEGF) with T-ES-CM compared with ES-CM. In conclusion, we suggest that factors released from ES cells with and without TGF-β2 treatment contain antiapoptotic factors that inhibit apoptosis in vitro and in vivo. We also suggest that T-ES-CM demonstrates additional beneficial effects that provide useful information for future therapeutic applications in regenerative medicine.Keywords
This publication has 44 references indexed in Scilit:
- Factors Released from Embryonic Stem Cells Stimulate c-kit-FLK-1 +ve Progenitor Cells and Enhance NeovascularizationAntioxidants & Redox Signaling, 2010
- Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppressionImmunobiology, 2010
- Embryonic Stem Cells in Cardiac Repair and RegenerationAntioxidants & Redox Signaling, 2009
- Factors released from embryonic stem cells inhibit apoptosis in H9c2 cells through PI3K/Akt but not ERK pathwayAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- p38 and ERK1/2 MAPKs mediate the interplay of TNF-α and IL-10 in regulating oxidative stress and cardiac myocyte apoptosisAmerican Journal of Physiology-Heart and Circulatory Physiology, 2007
- Factors released from embryonic stem cells inhibit apoptosis of H9c2 cellsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2007
- Transplanted embryonic stem cells following mouse myocardial infarction inhibit apoptosis and cardiac remodelingAmerican Journal of Physiology-Heart and Circulatory Physiology, 2007
- Transforming growth factor-β2 enhances differentiation of cardiac myocytes from embryonic stem cellsBiochemical and Biophysical Research Communications, 2005
- Adult Cardiac Stem Cells Are Multipotent and Support Myocardial RegenerationCell, 2003
- Reperfusion injury induces apoptosis in rabbit cardiomyocytes.Journal of Clinical Investigation, 1994